Jun 09, 2023 / 04:45PM GMT
Unidentified Participant
Hello, everyone, welcome. Today we're conducting a fireside chat with Lumos Pharma. My name is [Mac Chandler]. I'm on the biotech equity research team here at Jefferies. And with me, I have John McKew, President and CSO; and Lori Lawley, the CFO of Lumos Pharma. So thank you for joining us today.
Questions and Answers:
Unidentified ParticipantJust to begin, can you give us an overview of idiopathic pediatric growth hormone deficiency and how that compares to organic and a little bit about how that delineation impacts the development program for LUM-201?
John McKew - Lumos Pharma, Inc. - President & Chief Scientific Officer
Sure, would be happy to, Mac. So growth hormone deficiency is a spectrum from very growth them inefficient all the way up to just below normal. And across this kind of spectrum of growth hormone deficiency, there is a group of patients who are quite growth hormone deficient and maybe they have a break in their ability to have hypothalamic regulation of the pituitary release of
Trustpilot
